MNKD - MannKind Corp
MannKind Corp Logo

MNKD - MannKind Corp

https://www.mannkindcorp.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bullish
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy - MannKind ( NASDAQ:MNKD ) , United Therapeutics ( NASDAQ:UTHR )
Benzinga • 2 weeks, 5 days ago • score: 0.46
DANBURY, Conn. and BOSTON, Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation MNKD today announced that United Therapeutics Corporation UTHR has exercised its option-granted under the companies' 2018 license and collaboration agreement-to develop a second dry powder inhalation therapy.
Bullish
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal - scPharmaceuticals ( NASDAQ:SCPH ) , MannKind ( NASDAQ:MNKD )
Benzinga • 2 weeks, 6 days ago • score: 0.33
MannKind to buy scPharmaceuticals for $5.35 per share plus CVR, valuing the deal at up to $360 million. Furoscix sales rose 96% YoY in H1 2025, with Q3 sNDA submission planned for ReadyFlow Autoinjector. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here →
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United States. The company is headquartered in Westlake Village, California.

52W High
$7.63
52W Low
$3.38
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
1.02
Valuation
Rich
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
50.36
Forward P/E (<15 better)
42.55
EV/EBITDA (<8 favorable)
19.82
EV/Revenue (<3 favorable)
5.20
P/S (TTM) (<3 favorable)
5.63
P/B (<3 favorable)
N/A
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
1.66%
Institutions (25–75% balanced)
55.85%
Shares Outstanding
306,828,000
Float
300,980,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
As of 2025-06-30 (Overview)
Revenue (TTM)
301,736,000
Gross Profit (TTM)
226,025,000
EPS (TTM)
0.11
Profit Margin (>10% good)
0.11%
Operating Margin (TTM) (higher better)
0.14%
ROE (TTM) (>15% strong)
N/A
EPS YoY (Quarterly) (>10% good)
0.09
Revenue YoY (Quarterly) (>8% good)
0.06
Momentum
Bearish momentum
Value
0.5464
Previous
0.5524
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025